Peer-reviewedCC BYPharmaceutics
Optimization of a Dexamethasone and Vitamin E PLGA Microparticle Formulation Intended for Posterior Segment of the Eye to Cope with Patients’ Anti-Inflammatory Needs
- 1Unidad Docente de Farmacia y Tecnología Farmacéutica, Departamento de Ciencias Biomédicas, Facultad de Farmacia, Universidad de Alcalá, Ctra. de Madrid-Barcelona A-2, Km. 33,600, 28871 Alcalá de Henares, Spain
- 2Departamento de Farmacia Galénica y Tecnología Alimentaria, Universidad Complutense de Madrid, Plaza de Ramón y Cajal, 28040 Madrid, Spain
Related
- Dexmedetomidine Versus Dexamethasone in Pediatric Cardiac Surgery with Cardiopulmonary Bypass: An Exploratory Randomized Controlled Trial of Inflammatory Biomarkers and Opioid Consumption
- CD44-targeted hyaluronic acid nanohydrogels enhance macrophage uptake and preserve the anti-inflammatory efficacy of dexamethasone
- Nanometer Layer Coating to Lactose Particles for Optimization of Dexamethasone Pulmonary Delivery
- A zingiberene–selenium nanoparticle formulation modulates oxidative, inflammatory, and osteogenic responses during femoral fracture healing in rats
- Do Perineural Dexamethasone and Dexmedetomidine Improve Analgesia and Inflammatory Response After Lumbar Spine Surgery?
BibTeX
@article{villanueva2026optimization,
title = {{Optimization of a Dexamethasone and Vitamin E PLGA Microparticle Formulation Intended for Posterior Segment of the Eye to Cope with Patients’ Anti-Inflammatory Needs}},
author = {Javier Rodríguez Villanueva and Rocío Herrero-Vanrell and Irene Bravo-Osuna and Marta Vicario-de-la-Torre and Manuel Guzmán Navarro},
journal = {Pharmaceutics},
year = {2026},
month = sep,
url = {https://europepmc.org/article/PMC/PMC13708260},
note = {CC BY},
}
RIS
TY - JOUR
TI - Optimization of a Dexamethasone and Vitamin E PLGA Microparticle Formulation Intended for Posterior Segment of the Eye to Cope with Patients’ Anti-Inflammatory Needs
AU - Javier Rodríguez Villanueva
AU - Rocío Herrero-Vanrell
AU - Irene Bravo-Osuna
AU - Marta Vicario-de-la-Torre
AU - Manuel Guzmán Navarro
PY - 2026
DA - 2026/09/29
JO - Pharmaceutics
UR - https://europepmc.org/article/PMC/PMC13708260
SN - 1999-4923
ER -